Brief: Aurinia Pharmaceuticals Q2 EPS USD -0.08
03/08/2023 11:00
Aug 03 (Reuters) - Aurinia Pharmaceuticals Q2 product revenue USD 41.1 million. * Q2 net income USD -11.492 million * Q2 operating expenses USD 57.664 million * Q2 operating income USD -16.17 million * Q2 pretax profit USD -12.134 million
Recent news on Aurinia Pharmaceuticals
See all newsBrief: Aurinia Settles Patent Litigation With Teva
Canada's Aurinia Q2 revenue rises on LUPKYNIS sales
Brief: Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview
Brief: Lupkynis Associated With A Statistically Significant 53% Reduction In Risk Of Renal-Related Event Or Death